Stockreport

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments [Seeking Alpha]

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com
PDF Fasedienol has advantages as a non-systemic, low-abuse anxiolytic and is seeking Breakthrough Therapy Designation. VTGN's diverse product pipeline includes treatments [Read more]